Payment overview · 2025
General Payments
$53,903.29
362 reported records · 44 companies
Healthcare provider profile · identity verified
John W. Richard, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, KY · NPI 1124047717
Verified facts
What the public records show
CMS Open Payments records show John W. Richard, MD received $53,903.29 in general payments during 2025 across 362 reported records.
ConvaTec Inc. accounted for 62.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 67 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Creon, Eliquis, Farxiga, Gemtesa, Kerendia, Linzess, Nurtec Odt, Otezla, Ozempic, Paxlovid, Rexulti, Synthroid, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1873 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 548 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 461 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 87 records involving 83 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abilify Maintena by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1873 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $33,600.00 | 62.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $9,845.07 | 18.3% | 46 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,463.97 | 8.3% | 21 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $642.34 | 1.2% | 35 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $560.63 | 1.0% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $530.65 | 1.0% | 24 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $445.08 | 0.8% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $441.97 | 0.8% | 40 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $371.20 | 0.7% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $358.21 | 0.7% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $293.18 | 0.5% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $262.58 | 0.5% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $232.58 | 0.4% | 20 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $197.89 | 0.4% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $175.72 | 0.3% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $168.13 | 0.3% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $164.24 | 0.3% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $124.99 | 0.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $124.46 | 0.2% | 7 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $100.99 | 0.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $79.50 | 0.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $69.20 | 0.1% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $63.78 | 0.1% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $56.59 | 0.1% | 3 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $49.46 | 0.1% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $48.99 | 0.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $46.84 | 0.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.13 | 0.1% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $35.30 | 0.1% | 2 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $31.26 | 0.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $30.97 | 0.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $30.45 | 0.1% | 2 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $24.65 | 0.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $24.54 | 0.1% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $22.54 | 0.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.54 | 0.0% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.87 | 0.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.81 | 0.0% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.52 | 0.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.76 | 0.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.52 | 0.0% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.22 | 0.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.20 | 0.0% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $13.77 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Debt forgiveness | $33,600.00 | 7 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,720.00 | 8 |
| Food and Beverage | $6,890.73 | 339 |
| Travel and Lodging | $1,532.32 | 6 |
| Education | $160.24 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $33,600.00 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $9,758.19 | 42 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $4,463.97 | 21 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $651.94 | 36 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $560.63 | 24 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $437.13 | 17 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $371.20 | 11 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $358.21 | 23 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $317.62 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $293.18 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $289.51 | 30 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $262.58 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $232.58 | 20 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $203.07 | 20 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $194.44 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $185.65 | 17 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $168.13 | 5 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $165.33 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $164.24 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $106.80 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $100.99 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $100.99 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $94.16 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $93.52 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $92.14 | 6 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $80.12 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $79.50 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $69.20 | 4 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $69.01 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.55 | 6 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $56.59 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $49.46 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $49.46 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $48.99 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $48.99 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $47.34 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $46.84 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.51 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.45 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $36.18 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $35.81 | 4 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $35.30 | 2 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $31.26 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $23.82 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| REJOYN Normalized: rejoyn |
Device | Otsuka Pharmaceutical Development & Commercialization, Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $8.28 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $8.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1873 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 122 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 184 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 231 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 461 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 28 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 106 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
231 | 51 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
122 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1873 | 216 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 31 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
548 | 56 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
106 | 22 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
219 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
461 | 119 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
101 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
106 | 22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 87 supporting records · 83 recipient NPIs · example record 1225319985 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
106 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1873 | 216 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 25 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
110 | 32 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
184 | 29 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 2622 | 303 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2399 | 487 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2011 | 355 |
| Eliquis | Apixaban | 1873 | 216 |
| Amlodipine Besylate | Amlodipine Besylate | 1487 | 288 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1270 | 191 |
| Omeprazole | Omeprazole | 1211 | 278 |
| Sertraline Hcl | Sertraline Hcl | 1185 | 200 |
| Pantoprazole Sodium | Pantoprazole Sodium | 937 | 209 |
| Furosemide | Furosemide | 905 | 201 |
| Metoprolol Tartrate | Metoprolol Tartrate | 894 | 183 |
| Lisinopril | Lisinopril | 886 | 175 |
| Tramadol Hcl | Tramadol Hcl | 857 | 140 |
| Oxycodone Hcl | Oxycodone Hcl | 828 | 104 |
| Donepezil Hcl | Donepezil Hcl | 817 | 149 |
| Mirtazapine | Mirtazapine | 808 | 167 |
| Quetiapine Fumarate | Quetiapine Fumarate | 774 | 147 |
| Losartan Potassium | Losartan Potassium | 769 | 191 |
| Carvedilol | Carvedilol | 758 | 133 |
| Trazodone Hcl | Trazodone Hcl | 722 | 145 |
| Alprazolam | Alprazolam | 706 | 126 |
| Potassium Chloride | Potassium Chloride | 706 | 168 |
| Tamsulosin Hcl | Tamsulosin Hcl | 704 | 167 |
| Buspirone Hcl | Buspirone Hcl | 681 | 121 |
| Metformin Hcl | Metformin Hcl | 600 | 126 |
| Clopidogrel | Clopidogrel Bisulfate | 591 | 115 |
| Famotidine | Famotidine | 591 | 108 |
| Memantine Hcl | Memantine Hcl | 591 | 94 |
| Divalproex Sodium | Divalproex Sodium | 585 | 90 |
| Xarelto | Rivaroxaban | 548 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 520 | 124 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 487 | 82 |
| Ondansetron Hcl | Ondansetron Hcl | 461 | 189 |
| Ozempic | Semaglutide | 461 | 119 |
| Duloxetine Hcl | Duloxetine Hcl | 456 | 125 |
| Clonazepam | Clonazepam | 446 | 68 |
| Montelukast Sodium | Montelukast Sodium | 437 | 85 |
| Levetiracetam | Levetiracetam | 435 | 73 |
| Escitalopram Oxalate | Escitalopram Oxalate | 411 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 401 | 102 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 360 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 353 | 79 |
| Diclofenac Sodium | Diclofenac Sodium | 343 | 108 |
| Fluticasone Propionate | Fluticasone Propionate | 336 | 110 |
| Prednisone | Prednisone | 336 | 117 |
| Citalopram Hbr | Citalopram Hydrobromide | 312 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 302 | 62 |
| Baclofen | Baclofen | 298 | 55 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 283 | 39 |
| Azithromycin | Azithromycin | 276 | 158 |
| Paroxetine Hcl | Paroxetine Hcl | 276 | 62 |
| Lorazepam | Lorazepam | 273 | 65 |
| Bumetanide | Bumetanide | 268 | 68 |
| Ropinirole Hcl | Ropinirole Hcl | 267 | 61 |
| Nystatin | Nystatin | 261 | 107 |
| Januvia | Sitagliptin Phosphate | 250 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 72 |
| Jardiance | Empagliflozin | 247 | 43 |
| Simvastatin | Simvastatin | 241 | 50 |
| Olanzapine | Olanzapine | 240 | 40 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 239 | 68 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 236 | 36 |
| Allopurinol | Allopurinol | 235 | 51 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 235 | 59 |
| Linzess | Linaclotide | 231 | 51 |
| Methenamine Hippurate | Methenamine Hippurate | 231 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 230 | 52 |
| Spironolactone | Spironolactone | 225 | 41 |
| Entresto | Sacubitril/Valsartan | 219 | 34 |
| Mounjaro | Tirzepatide | 215 | 35 |
| Finasteride | Finasteride | 214 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 213 | 108 |
| Lactulose | Lactulose | 213 | 93 |
| Diazepam | Diazepam | 208 | 38 |
| Levofloxacin | Levofloxacin | 206 | 103 |
| Tizanidine Hcl | Tizanidine Hcl | 201 | 47 |
| Methylprednisolone | Methylprednisolone | 196 | 134 |
| Pregabalin | Pregabalin | 190 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 189 | 95 |
| Cephalexin | Cephalexin | 188 | 124 |
| Lacosamide | Lacosamide | 186 | 15 |
| Gemtesa | Vibegron | 184 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 181 | 44 |
| Topiramate | Topiramate | 179 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 176 | 56 |
| Testosterone Cypionate | Testosterone Cypionate | 174 | 41 |
| Ibuprofen | Ibuprofen | 170 | 59 |
| Alendronate Sodium | Alendronate Sodium | 168 | 33 |
| Risperidone | Risperidone | 164 | 26 |
| Bupropion Xl | Bupropion Hcl | 161 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 42 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 160 | 47 |
| Nifedipine Er | Nifedipine | 160 | 41 |
| Tradjenta | Linagliptin | 155 | 14 |
| Latanoprost | Latanoprost | 149 | 36 |
| Myrbetriq | Mirabegron | 140 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 137 | 65 |
| Breo Ellipta | Fluticasone/Vilanterol | 136 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 136 | 95 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 136 | 59 |
| Fluconazole | Fluconazole | 134 | 68 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 133 | 83 |
| Lamotrigine | Lamotrigine | 133 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 132 | 34 |
| Ondansetron Odt | Ondansetron | 128 | 50 |
| Ezetimibe | Ezetimibe | 126 | 24 |
| Farxiga | Dapagliflozin Propanediol | 122 | 16 |
| Meclizine Hcl | Meclizine Hcl | 119 | 39 |
| Ssd | Silver Sulfadiazine | 118 | 45 |
| Midodrine Hcl | Midodrine Hcl | 117 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 114 | 33 |
| Meloxicam | Meloxicam | 113 | 42 |
| Promethazine Hcl | Promethazine Hcl | 113 | 43 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 110 | 32 |
| Metformin Hcl Er | Metformin Hcl | 107 | 33 |
| Rexulti | Brexpiprazole | 106 | 22 |
| Morphine Sulfate | Morphine Sulfate | 104 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 102 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 31 |
| Atenolol | Atenolol | 101 | 21 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 101 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 99 | 42 |
| Aripiprazole | Aripiprazole | 98 | 21 |
| Estradiol | Estradiol | 98 | 15 |
| Mupirocin | Mupirocin | 96 | 61 |
| Warfarin Sodium | Warfarin Sodium | 93 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 92 | 19 |
| Glipizide | Glipizide | 92 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 92 | 16 |
| Sucralfate | Sucralfate | 92 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 91 | 62 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 33 |
| Valsartan | Valsartan | 89 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 24 |
| Clonidine Hcl | Clonidine Hcl | 88 | 34 |
| Novolog Flexpen | Insulin Aspart | 88 | 19 |
| Albuterol Sulfate | Albuterol Sulfate | 87 | 31 |
| Metolazone | Metolazone | 86 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 85 | 15 |
| Lidocaine Hcl | Lidocaine Hcl | 83 | 56 |
| Doxepin Hcl | Doxepin Hcl | 80 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 79 | 39 |
| Amoxicillin | Amoxicillin | 78 | 37 |
| Levemir Flexpen | Insulin Detemir | 76 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 74 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 74 | 26 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 72 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 72 | suppressed |
| Carbamazepine | Carbamazepine | 72 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 71 | 28 |
| Budesonide | Budesonide | 70 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 22 |
| Cefuroxime | Cefuroxime Axetil | 69 | 36 |
| Loperamide | Loperamide Hcl | 68 | 42 |
| Propranolol Hcl | Propranolol Hcl | 67 | 19 |
| Repatha Sureclick | Evolocumab | 67 | 16 |
| Brimonidine Tartrate | Brimonidine Tartrate | 66 | 17 |
| Methylphenidate Hcl | Methylphenidate Hcl | 65 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | suppressed |
| Digoxin | Digoxin | 63 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 63 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 62 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 62 | 21 |
| Aptiom | Eslicarbazepine Acetate | 61 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | suppressed |
| Metronidazole | Metronidazole | 61 | 25 |
| Prazosin Hcl | Prazosin Hcl | 61 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 61 | 15 |
| Ziprasidone Hcl | Ziprasidone Hcl | 61 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 60 | 39 |
| Nitroglycerin | Nitroglycerin | 60 | 46 |
| Amantadine | Amantadine Hcl | 59 | 11 |
| Erythromycin | Erythromycin Base | 59 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 32 |
| Cefdinir | Cefdinir | 58 | 34 |
| Methocarbamol | Methocarbamol | 58 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 58 | 21 |
| Primidone | Primidone | 57 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 57 | 12 |
| Vraylar | Cariprazine Hcl | 57 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 56 | 16 |
| Rivastigmine | Rivastigmine | 56 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 55 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 11 |
| Torsemide | Torsemide | 55 | 15 |
| Austedo | Deutetrabenazine | 53 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 53 | suppressed |
| Hydrocortisone | Hydrocortisone | 53 | suppressed |
| Timolol Maleate | Timolol Maleate | 53 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 53 | 19 |
| Lansoprazole | Lansoprazole | 51 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 50 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 49 | suppressed |
| Xifaxan | Rifaximin | 49 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | suppressed |
| Clotrimazole | Clotrimazole | 47 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 47 | 13 |
| Lidocaine | Lidocaine | 46 | 16 |
| Anastrozole | Anastrozole | 45 | 16 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 45 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 11 |
| Azelastine Hcl | Azelastine Hcl | 43 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 43 | suppressed |
| Klor-Con 10 | Potassium Chloride | 42 | suppressed |
| Methotrexate | Methotrexate Sodium | 42 | 12 |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 41 | suppressed |
| Glucagon Emergency Kit | Glucagon | 41 | 26 |
| Nystop | Nystatin | 41 | 24 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 40 | suppressed |
| Irbesartan | Irbesartan | 39 | suppressed |
| Movantik | Naloxegol Oxalate | 39 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Carisoprodol | Carisoprodol | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 36 | 22 |
| Celecoxib | Celecoxib | 36 | 12 |
| Clozapine | Clozapine | 36 | suppressed |
| Otezla | Apremilast | 36 | suppressed |
| Phenobarbital | Phenobarbital | 36 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 36 | 19 |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 34 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Creon | Lipase/Protease/Amylase | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 16 |
| Roflumilast | Roflumilast | 33 | suppressed |
| Constulose | Lactulose | 32 | 20 |
| Humalog | Insulin Lispro | 31 | 13 |
| Levemir | Insulin Detemir | 31 | 13 |
| Desmopressin Acetate | Desmopressin Acetate | 30 | suppressed |
| Lubiprostone | Lubiprostone | 30 | suppressed |
| Progesterone | Progesterone, Micronized | 30 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 30 | suppressed |
| Abilify Maintena | Aripiprazole | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | 11 |
| Alogliptin | Alogliptin Benzoate | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Enbrel Sureclick | Etanercept | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 25 |
| Premarin | Estrogens, Conjugated | 28 | suppressed |
| Valproic Acid | Valproic Acid | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 19 |
| Ertapenem | Ertapenem Sodium | 27 | 14 |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 27 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Restasis | Cyclosporine | 27 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 27 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | 11 |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Admelog | Insulin Lispro | 25 | suppressed |
| Cimetidine | Cimetidine | 25 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Triazolam | Triazolam | 24 | suppressed |
| Victoza 3-Pak | Liraglutide | 24 | suppressed |
| Admelog Solostar | Insulin Lispro | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 23 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 23 | 20 |
| Zonisamide | Zonisamide | 23 | suppressed |
| Bicalutamide | Bicalutamide | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Klayesta | Nystatin | 22 | 12 |
| Lumigan | Bimatoprost | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 14 |
| Ramipril | Ramipril | 22 | suppressed |
| Renvela | Sevelamer Carbonate | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Dayvigo | Lemborexant | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 21 | suppressed |
| Dronabinol | Dronabinol | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | 18 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Humulin R | Insulin Regular, Human | 20 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 20 | suppressed |
| Spravato | Esketamine Hcl | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 18 | 18 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Carbidopa | Carbidopa | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Insulin Aspart | Insulin Aspart | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 16 | 14 |
| Metformin Er Osmotic | Metformin Hcl | 16 | suppressed |
| Nateglinide | Nateglinide | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Acetylcysteine | Acetylcysteine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 15 |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Alphagan P | Brimonidine Tartrate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Viberzi | Eluxadoline | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 12 |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Humalog Junior Kwikpen | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lanthanum Carbonate | Lanthanum Carbonate | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53,903.29 · 362 records | ConvaTec Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, APLENZIN, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, COLLAGENASE SANTYL, CREON, DAXXIFY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, DUPIXENT, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INGREZZA, INNOVAMATRIX AC, Kerecis GraftGuide, Kerecis SurgiClose, Kerendia, Korlym, LEQVIO, LINZESS, LOREEV XR, MAVYRET, NEXLETOL, NUCALA, NURTEC ODT, NUZYRA, Natroba, Nayzilam, ONPATTRO, OTEZLA, Ohtuvayre, Omnipod, Ozempic, PAXLOVID, QULIPTA, REJOYN, RELISTOR, REPATHA, REXULTI, Rybelsus, SYNTHROID, Spinosad, Sunosi, Symbravo, TEZSPIRE, TONMYA, TREMFYA, TRUDHESA, TZIELD, UBRELVY, UZEDY, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZORYVE | 38 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error